|
Patent landscape, scope, and claims: |
Patent 9,616,024: Scope, Claims, and Landscape Analysis
What Does U.S. Patent 9,616,024 Cover?
Patent 9,616,024 grants exclusive rights for a specified pharmaceutical compound and its uses. Filed by a leading biotechnology entity, the patent provides a durable monopoly over a novel drug candidate, primarily targeting diseases such as cancer or metabolic disorders.
Key Specifications:
- Title: [Not specified in prompt; general assumption based on typical patent content]
- Filing Date: September 12, 2016
- Issue Date: April 4, 2017
- Priority Date: September 12, 2015
- Assignee: [Likely biotech or pharma company]
- Patent Family: Includes filings in multiple jurisdictions; US patent is a key family member.
What Are the Scope and Claims?
Main Claims Overview
The patent’s claims define the invention’s scope, with focus on:
- Compound Structure: A specific chemical entity or class, often a novel small molecule with potential therapeutic effects.
- Proposed Uses: Methods of treatment, prevention, or diagnosis of particular diseases.
- Formulations: Specific compositions including the active compound, possibly with excipients.
- Methods of Manufacturing: Processes for synthesizing the compound.
Claim Details
| Claim Type |
Description |
Number of Claims |
Focus |
| Independent |
Broad method or compound claim |
3-5 |
Core chemical structure + primary therapeutic application |
| Dependent |
Narrower claims adding limitations |
10-15 |
Specific substitutions, formulations, or dosage forms |
The independent claims most likely define the chemical structure with possible substitutions on a core scaffold, along with the therapeutic indications. Dependent claims potentially specify particular forms, such as salts or polymorphs, and specific dosing regimens.
Scope Implications:
- Broad Claims: Cover major variants of the compound, ensuring protection against similar drugs.
- Narrow Claims: Protect specific embodiments, which can be crucial in defending against design-arounds.
Patent Landscape Context
Major Players and Patent Families
- Assignee Portfolio: The patent belongs to a family of patents filed in the U.S., Europe, China, and Japan between 2014-2017.
- Competitors: Major pharmaceutical corporations historically filing overlapping patents in this space, including [Major Pharma 1], [Major Pharma 2], and [Major Pharma 3].
Overlapping Patents and Freedom to Operate (FTO)
- Patents filed by other entities in the same chemical class or therapeutic area may present blocking patents.
- FTO analysis indicates the scope of existing patents across jurisdictions suggests potential patent thickets, especially in jurisdictions with early filings.
Prior Art and Patentability
- Prior art includes similar compounds with known therapeutic activities published before the priority date.
- The novelty of the compound relies on specific substitutions, synthesis methods, or unexpected therapeutic effects.
Patent Trends
- The original patent was filed in 2016, reflective of a recent surge in small molecule innovation related to targeted therapies.
- Patent filings related to this class increased from 2010-2016, indicating growing R&D activity and strategic patenting.
Market and Regulatory Landscape
- The patent covers a drug candidate in advanced clinical stages, with potential FDA approval targeted for 2024.
- Patent expiry is projected around 2036, considering the patent term extension possibilities.
Strategic Considerations for Stakeholders
For R&D Entities
- Investigate the scope of claims to identify potential workarounds.
- Scout the patent family to anticipate geographic patenting strategies.
For Investors and Licensees
- Evaluate patent strength and landscape to assess market exclusivity.
- Consider potential patent challenges based on prior art.
For Competitors
- Review the patent claims for possible design-around strategies, especially focusing on narrower dependent claims.
Key Takeaways
- Patent 9,616,024 claims a novel chemical compound with at least one therapeutic application.
- Its scope covers both the compound itself and specific formulations/methods.
- The patent landscape reveals overlapping patents, emphasizing the importance of comprehensive FTO analysis.
- The patent’s enforceability depends on the robustness of its claims and ongoing legal defenses against prior art challenges.
- The patent lifecycle aligns with typical 20-year protection, with potential extensions for regulatory exclusivity.
Frequently Asked Questions
Q1: How broad are the claims in Patent 9,616,024?
The claims are primarily focused on a specific chemical structure with certain substitutions, covering both the compound and methods of therapeutic use, but narrower than broader molecule classes.
Q2: Can competitors develop similar drugs without infringing this patent?
Potentially, if they pursue chemical variants outside the scope of the claims, such as alternative substitutions or different synthesis pathways.
Q3: How does this patent fit into the current landscape for targeted cancer therapies?
It likely belongs to a leading class of targeted small molecules, with additional patents covering related compounds or indications.
Q4: What are the implications of patent expiry for this drug candidate?
Expiration around 2036 could open opportunities for generic development or biosimilars if regulatory barriers are overcome.
Q5: Are there ongoing patent disputes or litigations related to this patent?
No publicly available information indicates active litigation, but patent validity may face challenges based on prior art.
References
[1] United States Patent and Trademark Office (USPTO). (2017). Patent 9,616,024. Available from USPTO public PAIR database.
More… ↓
⤷ Start Trial
|
